Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dasatinib + capecitabine
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dasatinib + capecitabine is a **combination drug regimen** used primarily in oncology clinical trials, most notably for advanced breast cancer and metastatic colorectal cancer[1][2][3]. Dasatinib is a small-molecule tyrosine kinase inhibitor targeting BCR-ABL and Src family kinases, exhibiting anti-proliferative and anti-angiogenic activity. Capecitabine is an oral prodrug of 5-fluorouracil, inhibiting thymidylate synthase and interfering with DNA synthesis. Together, they act synergistically to inhibit cancer cell growth and angiogenesis, resulting in clinical benefit for some patients with advanced disease[1][3]. This combination's mechanism includes inhibition of kinase-driven signaling pathways (dasatinib) and blockade of DNA synthesis and repair (capecitabine). Primary indications under investigation include advanced breast cancer and metastatic colorectal cancer[1][2][3].
- Brand names
- SprycelXeloda
- Other names
- dasatinib and capecitabineBMS-354825 + capecitabine
02
Targets
RIPK1 (Receptor-interacting serine/threonine-protein kinase 1)SIK2 (Salt inducible kinase 2)ABL2 (ABL proto-oncogene 2, non-receptor tyrosine kinase)ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)FRK (Fyn-related Src family tyrosine kinase)SFK (SRC family kinases)EPHB2 (Ephrin type-B receptor 2)TS (Thymidylate synthase)DDR1 (Discoidin domain receptor 1)EPHA2 (Ephrin type-A receptor 2)
Beyond the preview
Go deeper on dasatinib + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dasatinib + capecitabine.